Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.73 USD
+0.07 (10.18%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.75 +0.02 (3.14%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MNPR 0.73 +0.07(10.18%)
Will MNPR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Other News for MNPR
12 Health Care Stocks Moving In Friday's After-Market Session
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Monopar files patent protecting its MNPR-101 radiopharma optimization findings
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent